Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Zoetis Inc. reported third-quarter 2026 revenue of $2.391 billion, compared with $2.422 billion a year earlier, and net income attributable to Zoetis of $591 million, versus $721 million. Adjusted net income was $720 million versus $754 million. For the first nine months, revenue was $7.121 billion versus $7.094 billion, while net income was $1.883 billion versus $2.049 billion. The 2025 comparisons were recast after the company eliminated a one-month financial reporting lag for international subsidiaries effective January 1, 2026.
Nine-month operating cash flow was $1.880 billion, compared with $2.056 billion. Treasury-stock purchases, including excise taxes paid, used $1.690 billion, and cash dividends paid were $666 million. Cash and cash equivalents were $1.333 billion as of September 30, 2026. Nine-month restructuring and certain acquisition- and divestiture-related costs were $142 million; third-quarter identifiable intangible asset impairment charges were $78 million.
Zoetis completed its acquisition of VitalRADS during the third quarter; the transaction did not have a material impact on its consolidated financial statements. Its agreement to acquire Neogen’s animal genomics business is subject to customary closing conditions and regulatory requirements, and Zoetis expects the transaction to conclude in early 2027.
Zoetis Inc. (ZTS) reported third-quarter 2026 revenue of $2.391 billion, down 1% year over year. Net income fell 18% to $591 million and diluted EPS fell 12% to $1.44. Adjusted net income was $720 million, down 5%, while adjusted diluted EPS rose 3% to $1.75; both adjusted measures are non-GAAP.
U.S. revenue declined 6% to $1.246 billion, including an 8% drop in companion-animal revenue; international revenue increased 4% to $1.116 billion. Livestock revenue increased 5% in the U.S. and 8% internationally. For full-year 2026, Zoetis raised adjusted net income guidance to $2.600 billion–$2.640 billion and adjusted diluted EPS to $6.25–$6.35, and narrowed revenue guidance to $9.220 billion–$9.320 billion.
The FDA approved Convenia RTU for Dogs in October, with availability expected in the first quarter of 2027. Simparica Trio received U.S. FDA Emergency Use Authorization for New World screwworm infestations in dogs and puppies.
Zoetis Inc. director Mark Stetter acquired 5.8516 phantom stock units on October 30, 2026, at a reported price of $79.7200 per share. Each unit represents one share of Zoetis common stock, and his reported position after the acquisition was 886.0267 units. The units reflect deferred cash retainer fees invested in the Zoetis stock fund, including dividend equivalents, and will be settled in cash following his separation from service.
Kristin C. Peck, Zoetis Inc.’s chief executive officer, acquired 720.1441 phantom stock units on October 9, 2026, listed at $26.17 per unit. Her reported position after the award was 66,915.0400 phantom stock units. Under the Zoetis Supplemental Savings Plan, the units are settled in cash following separation from service; transfers to an alternative investment fund are permitted, subject to Zoetis limits.
Zoetis Inc. Executive Vice President Kevin Esch acquired 360.0734 Phantom Stock Units on October 9, 2026; the reported price was $26.17 per share. His direct balance after the acquisition was 1,166.5046 Phantom Stock Units. The units were acquired under the Zoetis Supplemental Savings Plan and are settled in cash following separation from service. Transfers to an alternative investment fund are permitted, subject to Zoetis limiting their timing, frequency, and permissibility.
Zoetis Inc. Executive Vice President Rimma Driscoll acquired 277.7719 phantom stock units on October 9, 2026, pursuant to the Zoetis Supplemental Savings Plan. The units have 97 underlying shares of Zoetis common stock, and her reported direct holding afterward was 6,551.1542 phantom stock units. The units are settled in cash following separation from service. Driscoll may transfer them to an alternative investment fund, while Zoetis may limit the timing, frequency and permissibility of transfers.
Zoetis Inc. reported that Executive Vice President Julie Fuller acquired 367.7876 phantom stock units on October 9, 2026, at a reported $26.1700 per unit; her resulting balance was 2,480.4695 phantom stock units. The units were acquired under the Zoetis Supplemental Savings Plan and are settled in cash following separation from service. Fuller may transfer them to an alternative investment fund at any time, subject to Zoetis limits on transfer timing, frequency and permissibility.
Zoetis Inc. Executive Vice President Keith Sarbaugh acquired 303.4903 Phantom Stock Units on October 9, 2026; the award lists 106.1668 underlying common shares. His reported direct balance after the transaction was 2,668.3214 Phantom Stock Units. Acquired under the Zoetis Supplemental Savings Plan, the units are settled in cash following separation from service. Each unit represents a fraction of a phantom share plus cash-equivalent investments, which typically represent around 5% of the unit’s total value.
Zoetis Inc. Executive Vice President Astorga Jeannette Ferran acquired 52.9828 phantom stock units on October 9, 2026. The reported direct balance after the award was 2,349.1397 phantom stock units, corresponding to 18.5344 shares of common stock. The units are settled in cash following separation from service; each represents a fraction of a phantom share plus cash-equivalent investments, which typically represent around 5% of the unit’s total value.
Zoetis Inc. Executive Vice President Abhay U. Nayak acquired 321.4945 phantom stock units on October 9, 2026, bringing his reported direct balance to 5,022.0832 phantom stock units. The units were acquired under the Zoetis Supplemental Savings Plan and are settled in cash following separation from service. Each unit represents a fraction of a phantom share of Zoetis common stock plus cash-equivalent investments, which typically represent around 5% of total value. Zoetis may limit the timing, frequency and permissibility of transfers between investment funds.